Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Breast cancer

Ribosomal protein S6 kinase 90 kDa polypeptide 2 (RPS6KA2; RSK3); RPS6KA6 (RSK4); phosphoinositide-3 kinase (PI3K)

Cell culture and mouse studies suggest inhibiting RSK3 and RSK4 could be useful for treating breast cancers resistant to PI3K inhibitors. In cultured breast cancer cells, vector-mediated overexpression of RSK3 or RSK4 increased cell survival in the presence of PI3K pathway inhibitors compared with a control vector. In mouse xenograft models for human breast cancer, vector-mediated overexpression of RSK3 or RSK4 decreased tumor sensitivity to PI3K inhibitors compared with no overexpression. Next steps include identifying selective inhibitors of RSK3 and RSK4 and evaluating them in PI3K inhibitor-resistant tumors.

SciBX 6(20); doi:10.1038/scibx.2013.486
Published online May 23, 2013

Unpatented; licensing status not applicable

Serra, V. et al. J. Clin. Invest.; published online May 1, 2013;
doi:10.1172/JCI66343
Contact: So Young Kim, Duke University, Durham, N.C.
e-mail:
soyoung.kim@duke.edu

Contact:
José Baselga, Memorial Sloan-Kettering Cancer Center, New York, N.Y.
e-mail:
baselgaj@mskcc.org